Floatz logo

Angelica Sinensis

Cerebral Infarction

Dongfang Hospital Beijing University of Chinese MedicineN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Cerebral Infarction cohort.

Asset / SponsorPhaseRating
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Asan Medical Center
Phase 4BBB
Acetylsalicylic Acid
Sclnow Biotechnology Co., Ltd.
Phase 4BBB
Plavix
The Second Hospital of Anhui Medical University
Phase 4BBB
Human Urinary Kallidinogenase
Huisheng Chen
Phase 4BB
Hua Tuo Zai Zao Wan
Guangzhou University of Traditional Chinese Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Angelica Sinensis is also rated in:

prostate cancerDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →